Sachidanandam Kamakshi, Fagan Susan C, Ergul Adviye
Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy.
Cardiovasc Drug Rev. 2005 Summer;23(2):115-32. doi: 10.1111/j.1527-3466.2005.tb00160.x.
Experimental and clinical studies suggest that oxidative stress contributes to the development and progression of cardiovascular disease. However, clinical trials with classic vitamin antioxidants failed to demonstrate any benefit in cardiovascular outcomes. Recent advances in our understanding of mechanisms involved in free radical generation reinstate that a more comprehensive approach targeting the prevention of reactive oxygen species (ROS) formation early in the disease process may prove beneficial. Experimental studies and reviews in oxidative stress were selected to provide a better understanding of the roles of the reactive species in the initiation and progression of cardiovascular disease (CVD). Clinical studies that evaluated the efficacy of several classes of antioxidants in CVD were included in the second part of this review to discuss future therapeutic guidelines based on currently available evidence. In conclusion, before a potential role for antioxidants in the treatment of CVD is eliminated, more carefully designed studies with classic as well as new antioxidants in well-defined patient populations are warranted to provide a definitive answer.
实验和临床研究表明,氧化应激会促使心血管疾病的发生和发展。然而,使用经典维生素抗氧化剂的临床试验未能证明对心血管疾病转归有任何益处。我们对自由基生成相关机制认识的最新进展再次表明,在疾病进程早期采用更全面的方法来预防活性氧(ROS)形成可能是有益的。选取了关于氧化应激的实验研究和综述,以更好地了解活性物质在心血管疾病(CVD)起始和发展中的作用。本综述的第二部分纳入了评估几类抗氧化剂在CVD中疗效的临床研究,以根据现有证据讨论未来的治疗指南。总之,在排除抗氧化剂在CVD治疗中的潜在作用之前,有必要在明确界定的患者群体中开展更精心设计的经典抗氧化剂和新型抗氧化剂研究,以给出明确答案。